1. Scrip
  2. >>Business

Aptinyx Cashes In Post-Naurex Cache With $65m Series A

 
• By Mandy Jackson

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.

Evanston, Illinois-based Aptinyx will use its Series A cash to begin a Phase I clinical trial for its first drug candidate in mid-2016, to start multiple proof-of-concept studies during the first half of 2017, and to continue preclinical development for other programs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.